Updates
Bionaut growth, announcements and more
Bionaut Publishes a Protocol for Microformulations of Small Molecules, Biologics and Oligonucleotides Suitable for Micro-robotic Drug Delivery
Publication in the European Journal of Pharmaceutical Sciences demonstrates the ability to increase the loading of the therapeutic in a micro formulation compared to a liquid formulation. Full controlled release of the drug occurs within seven hours and is repeatable. Publication highlights the ability for Bionaut to have a high loading capacity suitable for therapeutic benefit across a range of therapeutic modalities.
Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases
Funds will be used to advance clinical development of the company’s lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder) and will also support further development of its proprietary Bionaut™ treatment platform, allowing future expansion of clinical targets and progression through Bionaut’s two accelerated FDA designations.
Dandy-Walker Alliance to Collaborate with Bionaut Labs
The Dandy-Walker Alliance is collaborating with Bionaut Labs to educate our constituency about an investigational new treatment for obstructive hydrocephalus associated with Dandy-Walker Syndrome.
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors
FDA Grants Humanitarian Use Device Designation to Bionaut Labs for Treatment of Dandy Walker Syndrome
The U.S. Food and Drug Administration (FDA) has granted the Company humanitarian use device (HUD) designation for BNL-201 for the local treatment of Dandy Walker Syndrome, a rare pediatric neurological disorder.
FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients
The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients. BNL-101 is a drug-device combination comprised of doxorubicin as the active drug component together with the company’s Bionaut™ microscale robots.
Bionaut Labs Debuts From Stealth Mode to Accelerate Development of New Precision Treatment Modality for Brain Disorders
Announced its launch backed by $20 million financing led by Khosla Ventures. Other investors in the syndicate included Upfront Ventures, Revolution, BOLD Capital, and Compound. Proceeds from the financing support the advancement of the Company’s lead therapeutic program in glioma through preclinical development, as well as help advance its program in Huntington’s disease.